Applications of H-D-Cha-OH in Industrial Manufacturing

H-D-Cha-OH serves as an advanced chiral building block in the synthesis of pharmaceuticals, biotech intermediates, peptide APIs, peptidomimetics, and fine chemical compounds. As a chemical raw material manufacturer specializing in synthetic amino acid derivatives, we support a range of downstream industries that require reliable, consistent, and specification-compliant input materials for high-precision chemical processes.

1. Active Pharmaceutical Ingredient (API) Peptide Synthesis

Peptide drug manufacturers use H-D-Cha-OH as a protected amino acid to build therapeutic oligopeptides and complex peptide structures, particularly where conformational rigidity or hydrophobic side chains are critical. The material enters peptide assembly via solid-phase synthesis or stepwise solution synthesis, where strict control over stereochemistry impacts the pharmacological properties of the final molecule. Applications extend to injectable peptide APIs and oral peptide formulations, requiring consistent chiral purity and low residual solvents to meet international pharmaceutical standards.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• USP/NF, EP 2.2.46 Purity tests
• FDA 21 CFR Part 211 (finished pharmaceuticals)
• Ph. Eur. 2.5.12 Amino acid analysis

Typical usage ratio

• 0.95 to 1.10 equivalents per coupling step in SPPS or LPPS, adjusted based on resin loading and target peptide complexity

Downstream process integration

• Utilized after initial resin loading in solid-phase peptide synthesis as a protected residue; coupling efficiency directly affects peptide yield and purity
• Employed as a free amino acid in solution phase condensation processes for selective introduction of cyclohexylalanine units

Final product types

• Synthetic peptide drug APIs (e.g., hormone analogues, peptide antibiotics)
• GLP-1 agonist injectable pharmaceuticals
• Oral lyophilized peptide tablets
• Diagnostics-grade oligopeptides

2. Biotech Research Reagents and Custom Peptide Services

CROs and biotech laboratories employ H-D-Cha-OH to produce custom peptides for research, molecular probes, and epitope mapping. Its chiral precision supports structural studies where non-standard residues influence protein folding and molecular interactions. High batch consistency and tailored specification control ensure reliable research outcomes, particularly in high-throughput synthesis and screening platforms. The demand for specialty amino acid analogs in peptide libraries highlights the value of supplier-level analytical support for purity and enantiomeric excess.

Industry compliance standards

• ISO 9001 Quality Management System (research reagent grade)
• OECD Guidelines for the Testing of Chemicals
• REACH Title IV (Registration of substances used in R&D)
• Internal QC: HPLC, MS, optical rotation specification reporting

Typical usage ratio

• 1.0 equivalent per target residue in combinatorial peptide synthesis; ratios modified for difficult sequences or incorporation into libraries

Downstream process integration

• Built into automated peptide chain elongation cycles in SPPS platforms
• Dissolved in buffered solvents for fragment condensation in dynamic combinatorial chemistry

Final product types

• Research-use-only peptide fragments
• Phage display screening peptides
• Epitope-mapping and antibody-generation substrates
• Mass spectrometry peptide standards

3. Peptidomimetic Drug Intermediate Manufacturing

Specialty fine chemical producers integrate H-D-Cha-OH during the synthesis of peptidomimetic cores for potential new chemical entities (NCEs). The cyclohexylalanine motif imparts unique pharmacokinetic features required in protease-resistant drug leads. Reliable supply with low-level impurities prevents by-product formation in downstream cyclization and functionalization steps, directly impacting project timelines during preclinical development and scale-up for regulatory filings.

Industry compliance standards

• ICH Q11: Development and Manufacture of Drug Substances
• Good Laboratory Practice (OECD GLP) for preclinical material
• ISO 17025 for analytical verification
• Valid method transfer documentation per ICH Q2(R2)

Typical usage ratio

• 0.9 to 1.2 molar equivalents in primary condensation; excess minimized to reduce downstream purification burden

Downstream process integration

• Fed into solution-phase fragment coupling as a protected α-amino acid
• Entered during macrocyclization or side-chain modification procedures used in peptidomimetic scaffold construction

Final product types

• Enzyme inhibitor leads
• Oral bioavailable peptidomimetics
• Small-molecule–peptide hybrid drugs
• Preclinical screening compounds

4. Cosmetic Bioactive Peptide Ingredient Production

Cosmeceutical manufacturers utilize H-D-Cha-OH in the synthesis of functional peptides used in skin care and anti-aging formulations. Its role as a non-proteinogenic residue enhances peptide stability and cellular uptake in topical applications. Close control over residual solvents and trace metals is essential to meet regulatory requirements for cosmetic ingredients distributed in the EU and North American markets, with clear specification for peptides destined for leave-on skin care products.

Industry compliance standards

• EU Regulation (EC) No 1223/2009 (Cosmetic Products Regulation)
• ISO 22716: Good Manufacturing Practices (cosmetic ingredients)
• CTFA/INCI registration guidelines
• US FDA Voluntary Cosmetic Registration Program (VCRP)

Typical usage ratio

• 0.95–1.05 equivalents per residue in peptide chain formation; specific ratio adjusted based on batch size and formulation scale

Downstream process integration

• Included at the residue elongation step in cosmetic peptide synthesis
• Purified peptide fragments formulated into serums and creams after lyophilization

Final product types

• Cosmetic bioactive pentapeptides and hexapeptides
• Anti-wrinkle topical treatment ingredients
• Peptide-enhanced eye creams
• Regenerative skin serums containing non-canonical amino acids